CN102584622A - Preparation method of L-2-aminobutanamide hydrochloride - Google Patents
Preparation method of L-2-aminobutanamide hydrochloride Download PDFInfo
- Publication number
- CN102584622A CN102584622A CN2012100342508A CN201210034250A CN102584622A CN 102584622 A CN102584622 A CN 102584622A CN 2012100342508 A CN2012100342508 A CN 2012100342508A CN 201210034250 A CN201210034250 A CN 201210034250A CN 102584622 A CN102584622 A CN 102584622A
- Authority
- CN
- China
- Prior art keywords
- amino
- butanamide
- preparation
- bullion
- schiff bases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HDBMIDJFXOYCGK-DFWYDOINSA-N (2s)-2-aminobutanamide;hydrochloride Chemical compound Cl.CC[C@H](N)C(N)=O HDBMIDJFXOYCGK-DFWYDOINSA-N 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000002262 Schiff base Substances 0.000 claims abstract description 29
- 150000004753 Schiff bases Chemical class 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 20
- HNNJFUDLLWOVKZ-UHFFFAOYSA-N 2-aminobutanamide Chemical compound CCC(N)C(N)=O HNNJFUDLLWOVKZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000012452 mother liquor Substances 0.000 claims abstract description 13
- 230000006340 racemization Effects 0.000 claims abstract description 12
- 150000003934 aromatic aldehydes Chemical class 0.000 claims abstract description 10
- 238000000926 separation method Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000007787 solid Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 235000010755 mineral Nutrition 0.000 claims description 8
- 150000007530 organic bases Chemical class 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 6
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 6
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 5
- -1 monosubstituted phenyl Chemical group 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- FIVVRGAOWICBAV-CGSHOFOJSA-N (2s)-2-aminobutanamide;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound CC[C@H](N)C(N)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O FIVVRGAOWICBAV-CGSHOFOJSA-N 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 claims description 3
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 claims description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 3
- 235000015320 potassium carbonate Nutrition 0.000 claims description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 3
- LMHHRCOWPQNFTF-UHFFFAOYSA-N s-propan-2-yl azepane-1-carbothioate Chemical compound CC(C)SC(=O)N1CCCCCC1 LMHHRCOWPQNFTF-UHFFFAOYSA-N 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 claims description 3
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 claims description 3
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 claims description 3
- LPSKDVINWQNWFE-UHFFFAOYSA-M tetrapropylazanium;hydroxide Chemical compound [OH-].CCC[N+](CCC)(CCC)CCC LPSKDVINWQNWFE-UHFFFAOYSA-M 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000010977 unit operation Methods 0.000 abstract description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 14
- 238000001291 vacuum drying Methods 0.000 description 12
- 238000005406 washing Methods 0.000 description 9
- FIVVRGAOWICBAV-DFWYDOINSA-N (2s)-2-aminobutanamide;2,3-dihydroxybutanedioic acid Chemical compound CC[C@H](N)C(N)=O.OC(=O)C(O)C(O)C(O)=O FIVVRGAOWICBAV-DFWYDOINSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 4
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 101000584505 Homo sapiens Synaptic vesicle glycoprotein 2A Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 206010061334 Partial seizures Diseases 0.000 description 2
- 102100030701 Synaptic vesicle glycoprotein 2A Human genes 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- HDBMIDJFXOYCGK-UHFFFAOYSA-N 2-aminobutanamide;hydrochloride Chemical compound Cl.CCC(N)C(N)=O HDBMIDJFXOYCGK-UHFFFAOYSA-N 0.000 description 1
- YAQLSKVCTLCIIE-UHFFFAOYSA-N 2-bromobutyric acid Chemical compound CCC(Br)C(O)=O YAQLSKVCTLCIIE-UHFFFAOYSA-N 0.000 description 1
- IPXNXMNCBXHYLQ-UHFFFAOYSA-N 2-pyrrolidin-1-ylacetic acid Chemical compound OC(=O)CN1CCCC1 IPXNXMNCBXHYLQ-UHFFFAOYSA-N 0.000 description 1
- POQJHLBMLVTHAU-UHFFFAOYSA-N 3,4-Dimethylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1C POQJHLBMLVTHAU-UHFFFAOYSA-N 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- LMZFTGWSDNSZDR-UHFFFAOYSA-K C(=O)([O-])C(O)C(O)C(=O)[O-].Cl[Na].[Na+].[Na+] Chemical compound C(=O)([O-])C(O)C(O)C(=O)[O-].Cl[Na].[Na+].[Na+] LMZFTGWSDNSZDR-UHFFFAOYSA-K 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005695 dehalogenation reaction Methods 0.000 description 1
- PAWJTXKFKIOATE-UHFFFAOYSA-N ethylbenzene formaldehyde Chemical compound O=C.CCC1=CC=CC=C1 PAWJTXKFKIOATE-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention provides a preparation method of L-2-aminobutanamide hydrochloride. The method comprises the following steps: based on crude DL-2-aminobutanamide as a starting raw material, reacting with aromatic aldehyde to form DL-Schiff-base, separating, dissociating, and salifying to obtain L-2-aminobutanamide hydrochloride, wherein the Schiff base can be directly separated by using L-tartaric acid, the chiral purity ee value of the product is no less than 99%, the quality is stable, and the separation mother liquor can be recycled through racemization. According to the invention, the raw materials used in each step of the method are cheap and available, the unit operations are simple and safe, the post-treatment is convenient, the requirements on the equipment are low and the method is suitable for industrialized production.
Description
Technical field
The present invention relates to the preparation of pharmaceutical intermediate, be specifically related to a kind of preparation method of chiral drug UCB-L 059 midbody L-2-amino-butanamide hydrochloride.
Background technology
UCB-L 059 (Levetiracetam) is a kind of novel antiepileptic drug, all can reduce the epilepsy partial seizures as assisting therapy or single therapy.Obtained drugs approved by FDA in 1999, the assisting therapy of the partial seizures that is used to be grown up, the assisting therapy that its oral tablet in 2005 and solution are got permission to be used for 4 years old and above children and youth epilepsy is shown effect first.Go on the market in China's approval in March, 2007.These article have the unique effect mechanism that is different from other antiepileptic drugs; It is synaptophysin SV2A bonded antiepileptic drug in only so far confirmation and the presynaptic nerve ending; Its with SV2A combine can suppress the paradoxical discharge in the epilepsy loop, thereby the blocking-up epileptic seizures.These article have that bioavailability height, pharmacokinetics are linear, protein binding rate is low, liver metabolism is few, can obtain characteristics such as stabilised blood concentration and drug interaction be little fast, are that clinical application is than safe drugs.
UCB 6474 has R, two kinds of enantiomers of S, and dextrorotatory form has only slight or unconspicuous drug action for suppressing epileptic seizures, and UCB-L 059 then is a kind of antiepileptic drug safely and efficiently.The synthetic key of UCB-L 059 is the optical purity of control levoisomer in reaction process.
The patent No. of UCB. S.A. (BE) Bruxelles Belgium is that the patent of US4696943 is mentioned UCB-L 059 first; And with (R, S)-alpha-ethyl-2-oxo-1-pyrrolidine acetic acid is a raw material, in solvent benzol, splits with (R)-(+)-Alpha-Methyl benzylamine; Obtain (S)-alpha-ethyl-2-oxo-the 1-pyrrolidine acetic acid; And then amidation, obtain UCB-L 059, shown in following synthetic route.This method has not only been used hypertoxic solvent benzol, should avoid the use of in the industrial production, and the optical purity of the compound that obtains of this method is lower.
Usually adopt two kinds of methods to synthesize in the later patents, a kind of is that the optically active amino acid of employing is starting raw material, and another kind is that salify splits in building-up process.
The patent No. is that disclosing with the L-methionine(Met) in the patent document of CN101550099 is raw material, through the hydroxylation of first sulfydryl, and amino acidylate, the amidation of carboxylic acid, in the method for preparing UCB-L 059 through steps such as cyclizations.Concrete synthetic route is as follows, and visible this method has been used hypertoxic methyl iodide.
The patent No. is that to disclose with the L-Threonine be raw material to the patent document of CN101550100; Prepare the method for UCB-L 059 through steps such as over-churning, halo, dehalogenation, acidylate, cyclizations; Concrete synthetic route is as follows, and the shortcoming of this method is that synthesising reacting time is longer.
The patent No. be the patent document of EP1566376 to disclose with the L-2-propalanine be raw material, through the method that esterification, ammonia are separated, salify, cyclization four-step reaction prepare UCB-L 059, concrete synthetic route is as follows.
Publication number be the patent document of WO03014080 to disclose with the L-2-propalanine be raw material, through esterification, take off HBr, close ring, ammonia is separated the method that four-step reaction prepares UCB-L 059, concrete synthetic route is as follows.
Though above two lines step is few, starting raw material L-2-propalanine costs an arm and a leg, and cost is higher.
The L-2-amino-butanamide hydrochloride is the key intermediate of UCB-L 059 building-up process, important chiral source.Can behind synthetic L-2-amino-butanamide hydrochloride, close ring preparation UCB-L 059 with the 4-chlorobutanoylchloride.The patent No. is the patent document of CN1583721A, is that raw material is when splitting, because the existence of alkali with racemization DL-2-amino-butanamide hydrochloride shown in the following synthetic route; Like sodium hydroxide; Make the inorganic salts of quite a few, like sodium-chlor, sodium tartrate etc. can precipitate with product simultaneously separates out; Cause separation difficulty, the product purity that obtains is not high.And the isomer biological activity of D-form does not have utility value far below the isomer of L-configuration, does not carry out recycling.
The patent No. is that the patent document of CN101130504B discloses with the 2-bromo-butyric acid is that raw material obtains the 2-propalanine through amination in ammoniacal liquor; Separate the free alkali DL-2-amino-butanamide bullion that obtains DL through esterification, ammonia; Adopt the method for half amount fractionation again, obtain the method for optically active L-2-amino-butanamide hydrochloride.And carried out the racemization recycling to splitting mother liquor.Concrete synthetic route is as follows.But in actual production, find to make a big impact for follow-up fractionation operation, cause product suction filtration and quality unstable, receive certain limitation in the production because DL-2-amino-butanamide bullion contains more unknown impuritie.
Summary of the invention
The objective of the invention is to overcome the deficiency of above-mentioned prior art, the preparation method of a kind of purity height, high, the stay-in-grade L-2-amino-butanamide hydrochloride of yield is provided.
For achieving the above object, the present invention adopts following technical scheme:
A kind of preparation method of L-2-amino-butanamide hydrochloride shown in following synthetic route, comprises the steps:
1. purifying: the DL-2-amino-butanamide bullion of DL is soluble in water, add aromatic aldehyde, in-10～50 ℃ of reactions 1～10 hour, form schiff bases and separate out, to filter, drying obtains the schiff bases of the DL of purifying;
2. split: the schiff bases of DL is dissolved in organic solvent, in-10～60 ℃, splits with resolving agent L-tartrate, solid-liquid separation obtains optically active L-2-amino-butanamide L-tartrate solid and splits mother liquor;
3. free salify: L-2-amino-butanamide L-tartrate is suspended in the organic solvent, feeds ammonia, stirred 1～24 hour to saturated; Filter, filtrating feeds hydrogen chloride gas at-10～40 ℃, regulates pH=1～5; Filter, obtain the L-2-amino-butanamide hydrochloride after the drying treatment.
Further, the aromatic aldehyde of said step in 1. has following structure: Ar-CHO, and wherein Ar is an aryl.
Further, said aryl comprises phenyl, monosubstituted phenyl or polysubstituted phenyl.
Further, said step 1. in DL-2-amino-butanamide bullion and the weight ratio of water of DL be 1: 1～100, the DL-2-amino-butanamide bullion of DL and the mol ratio of aromatic aldehyde are 1: 0.8～2.
Further, said step 2. and the organic solvent 3. be in anhydrous methanol, absolute ethyl alcohol, anhydrous propyl alcohol, anhydrous isopropyl alcohol, anhydrous normal butyl alcohol and the anhydrous tertiary butanol one or more.
Further, said step 2. in schiff bases and the weight ratio of organic solvent of DL be 1: 1～50.
Further, said method also comprises 4. racemization: mineral alkali or organic bases are added split mother liquor ,-10～60 ℃ of stirring reactions 1～24 hour; Underpressure distillation is steamed and is desolventized; Obtain the schiff bases bullion of DL, bullion adds in the entry in-10～50 ℃ of following stirrings 1～12 hour, filtration; Drying obtains the schiff bases of pure DL.
Further; The mineral alkali of said step in 4. is alkali metal hydroxide or alkaline carbonate, comprises in yellow soda ash, salt of wormwood, cesium carbonate, Quilonum Retard, sodium hydrogencarbonate, saleratus, Pottasium Hydroxide, sodium hydroxide, Lithium Hydroxide MonoHydrate and the hydrated barta one or more; Described organic bases is one or more in sodium methylate, sodium ethylate, sodium isopropylate, sodium tert-butoxide, potassium tert.-butoxide, TMAH, tetraethyl ammonium hydroxide, TPAOH and the TBAH.
Further, the mol ratio of organic bases or mineral alkali and fractionation mother liquor is 0.01～0.5: 1.
Further, the schiff bases bullion of the DL of said step in 4. and the weight ratio of water are 1: 1～100.
The invention provides a kind of preparation method of L-2-amino-butanamide hydrochloride, it is a starting raw material with DL-2-amino-butanamide bullion, form the schiff bases of DL with aromatic aldehyde after, through split, free, salify obtains the L-2-amino-butanamide hydrochloride.Wherein, schiff bases can directly split product chiral purity ee value >=99% with L-tartrate; Steady quality splits directly racemization recycling of mother liquor, the inventive method respectively to go on foot starting material cheap and easy to get; Unit operation is simple and safe; Convenient post-treatment, equipment requirements is low, is fit to industrialized production.
Embodiment
In order to make the object of the invention, technical scheme and advantage clearer,, the present invention is further elaborated below in conjunction with embodiment.Should be appreciated that specific embodiment described herein only in order to explanation the present invention, and be not used in qualification the present invention.
Embodiment 1:
1.1 purifying:
In the 1000ml flask, 100g DL-2-amino-butanamide bullion to be dissolved in the 500ml water, is added the 106g phenyl aldehyde, solid is slowly separated out; Continue under the room temperature to stir 5 hours, filter, wash with less water; 30 ℃ of vacuum-dryings of solid obtain the schiff bases 158g of DL, yield 85.0%.
Preferred version as the step of purifying; Aromatic aldehyde can also be for salicylic aldehyde, p-tolualdehyde, to ethylbenzene formaldehyde, 3,4-dimethylbenzaldehyde and 2,4; A kind of in the 6-trimethylbenzaldehyde and several kinds; Wherein, the mol ratio of DL-2-amino-butanamide bullion and aromatic aldehyde can be 1: 0.8～2, be preferably 1: 1～and 1.5; The DL-2-amino-butanamide bullion of DL and the weight ratio of water can be 1: 1～100, be preferably 1: 5～and 20.
1.2 split:
In the 1000ml flask, add schiff bases 150g, absolute ethyl alcohol 500ml; Stirring makes the solid dissolving, adds 30g L-tartrate/150ml ethanol solution at 20～25 ℃, 20～25 ℃ of reactions 6 hours; Filter, use a small amount of absolute ethanol washing, 70 ℃ of vacuum-dryings of solid are to constant weight; Obtain L-2-amino-butanamide tartrate solid 63.0g, yield 44.5%.
Preferred version as splitting step; Organic solvent can also be selected one or more in anhydrous methanol, anhydrous propyl alcohol, anhydrous isopropyl alcohol, anhydrous normal butyl alcohol and the anhydrous tertiary butanol; Wherein the weight ratio of the schiff bases of DL and organic solvent is 1: 1～50, and first-selection is 1: 5～10.
1.3 free salify:
In the 500ml flask, add L-2-amino-butanamide tartrate 60g, absolute ethyl alcohol 300ml is cooled to 0～5 ℃, feeds ammonia to saturated, continues under the room temperature to stir 10 hours, filters, and uses a small amount of absolute ethanol washing.Filtrating is cooled to 0～5 ℃, and Dropwise 35 % ethanol solution hydrochloride is regulated pH=1～5, filters; Use a small amount of absolute ethanol washing, 60～70 ℃ of vacuum-dryings of solid obtain L-2-amino-butanamide ite 42.3g to constant weight; Yield 91%, chemical purity 99.7%, optical purity ee value 99.5%.
1.4 racemization:
The mother liquor 665ml that embodiment 1.2 is obtained adds in the 1000ml flask, adds sodium ethylate 2.95 grams, is heated to 45～50 ℃, reacts 2 hours; Concentrating under reduced pressure reclaims solvent, and residual solution adds 400ml water, and solid is slowly separated out; Continue under the room temperature to stir 5 hours, filter, wash with less water; 30 ℃ of vacuum-dryings of solid obtain the schiff bases 68.5g of DL, yield 83%.
Preferred version as the racemization step; Mineral alkali is alkali metal hydroxide or alkaline carbonate, can select in yellow soda ash, salt of wormwood, cesium carbonate, Quilonum Retard, sodium hydrogencarbonate, saleratus, Pottasium Hydroxide, sodium hydroxide, Lithium Hydroxide MonoHydrate and the hydrated barta one or more particularly; Organic bases can be selected a kind of in sodium methylate, sodium ethylate, sodium isopropylate, sodium tert-butoxide, potassium tert.-butoxide, TMAH, tetraethyl ammonium hydroxide, TPAOH and the TBAH and several kinds, is preferably sodium methylate, sodium ethylate.Wherein, the consumption of organic bases or mineral alkali can be 0.01～0.5: 1 with the mol ratio that splits mother liquor, is preferably 0.01～0.1: 1.
As the preferred version of racemization step, the schiff bases bullion of the DL that racemization obtains and the weight ratio of water can be 1: 1～100, be preferably 1: 5～and 20.
Embodiment 2:
2.1 purifying:
In the 1000ml flask, 100g DL-2-amino-butanamide bullion is dissolved in the 650ml water, add the 106g phenyl aldehyde, solid is slowly separated out; Continue under the room temperature to stir 5 hours, filter, wash with less water; 30 ℃ of vacuum-dryings of solid obtain the schiff bases 162g of DL, yield 87.1%.
2.2 split:
In the 1000ml flask, add schiff bases 150g, anhydrous methanol 500ml; Stirring makes the solid dissolving, adds 30g L-tartrate/150ml absolute methanol solution at 20～25 ℃, 20～25 ℃ of reactions 6 hours; Filter, with a small amount of anhydrous methanol washing, 60 ℃ of vacuum-dryings of solid are to constant weight; Obtain L-2-amino-butanamide tartrate solid 58.8g, yield 41.5%.
2.3 free salify:
In the 500ml flask, add L-2-amino-butanamide tartrate 50g, absolute ethyl alcohol 250ml is cooled to 0～5 ℃, feeds ammonia to saturated, continues under the room temperature to stir 10 hours, filters, and uses a small amount of absolute ethanol washing.Filtrating is cooled to 0～5 ℃, and Dropwise 35 % ethanol solution hydrochloride is regulated pH=1～5, filters; Use a small amount of absolute ethanol washing, 60～70 ℃ of vacuum-dryings of solid obtain L-2-amino-butanamide hydrochloride 37.3g to constant weight; Yield 95%, chemical purity 99.2%, optical purity ee value 99.6%.
2.4 racemization:
The mother liquor 670ml that embodiment 2.2 is obtained adds in the 1000ml flask, adds sodium methylate 1.28 grams, is heated to 35～40 ℃, reacts 5 hours; Concentrating under reduced pressure reclaims solvent, and residual solution adds 400ml water, and solid is slowly separated out; Continue under the room temperature to stir 5 hours, filter, wash with less water; 30 ℃ of vacuum-dryings of solid obtain the schiff bases 74.5g of DL, yield 85%.
Embodiment 3:
3.1 purifying:
In the 1000ml flask, 100g DL-2-amino-butanamide bullion is dissolved in the 650ml water, add the 122g phenyl aldehyde, solid is slowly separated out; Continue under the room temperature to stir 5 hours, filter, wash with less water; 30 ℃ of vacuum-dryings of solid obtain the schiff bases 187g of DL, yield 93.0%.
3.2 split:
In the 1000ml flask, add schiff bases 180g, absolute ethyl alcohol 500ml; Stirring makes the solid dissolving, adds 33g L-tartrate/150ml ethanol solution at 20～25 ℃, 20～25 ℃ of reactions 6 hours; Filter, use a small amount of absolute ethanol washing, 70 ℃ of vacuum-dryings of solid are to constant weight; Obtain L-2-amino-butanamide tartrate solid 70.0g, yield 45.0%.
3.3 free salify:
In the 500ml flask, add L-2-amino-butanamide tartrate 60g, absolute ethyl alcohol 300ml is cooled to 0～5 ℃, feeds ammonia to saturated, continues under the room temperature to stir 10 hours, filters, and uses a small amount of absolute ethanol washing.Filtrating is cooled to 0～5 ℃, and Dropwise 35 % ethanol solution hydrochloride is regulated pH=1～5, filters; Use a small amount of absolute ethanol washing, 60～70 ℃ of vacuum-dryings of solid obtain L-2-amino-butanamide ite 44.2g to constant weight; Yield 94%, chemical purity 99.1%, optical purity ee value 99.3%.
3.4 racemization:
The mother liquor 650ml that embodiment 1.2 is obtained adds in the 1000ml flask, adds sodium ethylate 1.5 grams, is heated to 45～50 ℃, reacts 2 hours; Concentrating under reduced pressure reclaims solvent, and residual solution adds 400ml water, and solid is slowly separated out; Continue under the room temperature to stir 5 hours, filter, wash with less water; 30 ℃ of vacuum-dryings of solid obtain the schiff bases 86.5g of DL, yield 87.0%.
The above is merely preferred embodiment of the present invention, is not to be used for limiting practical range of the present invention; If do not break away from the spirit and scope of the present invention, the present invention is made amendment or is equal to replacement, all should be encompassed in the middle of the protection domain of claim of the present invention.
Claims (10)
1. the preparation method of a L-2-amino-butanamide hydrochloride is characterized in that, comprises the steps: shown in the following synthetic route of said method
1. purifying: the DL-2-amino-butanamide bullion of DL is soluble in water, add aromatic aldehyde, in-10～50 ℃ of reactions 1～10 hour, form schiff bases and separate out, to filter, drying obtains the schiff bases of the DL of purifying;
2. split: the schiff bases of DL is dissolved in organic solvent, in-10～60 ℃, splits with resolving agent L-tartrate, solid-liquid separation obtains optically active L-2-amino-butanamide L-tartrate solid and splits mother liquor;
3. free salify: L-2-amino-butanamide L-tartrate is suspended in the organic solvent, feeds ammonia, stirred 1～24 hour to saturated; Filter, filtrating feeds hydrogen chloride gas at-10～40 ℃, regulates pH=1～5; Filter, obtain the L-2-amino-butanamide hydrochloride after the drying treatment.
2. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 1 is characterized in that, the aromatic aldehyde of said step in 1. has following structure: Ar-CHO, and wherein Ar is an aryl.
3. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 2 is characterized in that, said aryl comprises phenyl, monosubstituted phenyl or polysubstituted phenyl.
4. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 1; It is characterized in that; Said step 1. in DL-2-amino-butanamide bullion and the weight ratio of water of DL be 1: 1～100, the DL-2-amino-butanamide bullion of DL and the mol ratio of aromatic aldehyde are 1: 0.8～2.
5. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 1; It is characterized in that, said step 2. and the organic solvent 3. be in anhydrous methanol, absolute ethyl alcohol, anhydrous propyl alcohol, anhydrous isopropyl alcohol, anhydrous normal butyl alcohol and the anhydrous tertiary butanol one or more.
6. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 1 is characterized in that, said step 2. in schiff bases and the weight ratio of organic solvent of DL be 1: 1～50.
7. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 1 is characterized in that, said method also comprises 4. racemization: mineral alkali or organic bases are added the fractionation mother liquor;-10～60 ℃ of stirring reactions 1～24 hour, underpressure distillation was steamed and is desolventized, and obtains the schiff bases bullion of DL; Bullion adds in the entry-10～50 ℃ of following stirrings 1～12 hour; Filter, drying obtains the schiff bases of pure DL.
8. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 7; It is characterized in that; The mineral alkali of said step in 4. is alkali metal hydroxide or alkaline carbonate, comprises in yellow soda ash, salt of wormwood, cesium carbonate, Quilonum Retard, sodium hydrogencarbonate, saleratus, Pottasium Hydroxide, sodium hydroxide, Lithium Hydroxide MonoHydrate and the hydrated barta one or more; Described organic bases is one or more in sodium methylate, sodium ethylate, sodium isopropylate, sodium tert-butoxide, potassium tert.-butoxide, TMAH, tetraethyl ammonium hydroxide, TPAOH and the TBAH.
9. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 8 is characterized in that, the mol ratio of organic bases or mineral alkali and fractionation mother liquor is 0.01～0.5: 1.
10. the preparation method of a kind of L-2-amino-butanamide hydrochloride according to claim 7 is characterized in that, the schiff bases bullion of the DL of said step in 4. and the weight ratio of water are 1: 1～100.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210034250 CN102584622B (en) | 2012-02-15 | 2012-02-15 | Preparation method of L-2-aminobutanamide hydrochloride |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210034250 CN102584622B (en) | 2012-02-15 | 2012-02-15 | Preparation method of L-2-aminobutanamide hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102584622A true CN102584622A (en) | 2012-07-18 |
| CN102584622B CN102584622B (en) | 2013-08-14 |
Family
ID=46473955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210034250 Active CN102584622B (en) | 2012-02-15 | 2012-02-15 | Preparation method of L-2-aminobutanamide hydrochloride |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102584622B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102863354A (en) * | 2012-09-06 | 2013-01-09 | 浙江华海药业股份有限公司 | Method for dynamically splitting 2-amino-butyrylamide |
| CN102898324A (en) * | 2012-10-19 | 2013-01-30 | 阜新龙瑞化工有限责任公司 | Method for preparing (S)-2-aminobutanamide hydrochloride |
| CN109503408A (en) * | 2019-01-07 | 2019-03-22 | 宁波赜军医药科技有限公司 | A kind of method for splitting of (S)-(+) -2- amino-butanamide hydrochloride |
| CN109678752A (en) * | 2018-12-27 | 2019-04-26 | 南京红杉生物科技有限公司 | A kind of method of asymmetric transformation synthesis L-2- amino-butanamide hydrochloride |
| CN113582903A (en) * | 2021-08-25 | 2021-11-02 | 沧州那瑞化学科技有限公司 | Method for synthesizing medicine for treating epilepsy by using L-2-aminobutanamide hydrochloride |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583721A (en) * | 2003-08-20 | 2005-02-23 | 天津泰普药品科技发展有限公司 | Synthesis of (S)-alpha-ethyl-2-oxi-1-pentazane acetamide |
| CN101130504A (en) * | 2006-08-25 | 2008-02-27 | 雅本化学（苏州）有限公司 | Synthesis, split and racemization of chirality medicament levetiracetam midbody (S)-(+)-2-amido butyramide hydrochlorate |
-
2012
- 2012-02-15 CN CN 201210034250 patent/CN102584622B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583721A (en) * | 2003-08-20 | 2005-02-23 | 天津泰普药品科技发展有限公司 | Synthesis of (S)-alpha-ethyl-2-oxi-1-pentazane acetamide |
| CN101130504A (en) * | 2006-08-25 | 2008-02-27 | 雅本化学（苏州）有限公司 | Synthesis, split and racemization of chirality medicament levetiracetam midbody (S)-(+)-2-amido butyramide hydrochlorate |
Non-Patent Citations (2)
| Title |
|---|
| 廖本仁等: "苯甘氨酰胺结晶诱导的动态动力学拆分", 《有机化学》 * |
| 杨艺虹等: "对羟基苯甘氨酸拆分技术进展", 《化工进展》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102863354A (en) * | 2012-09-06 | 2013-01-09 | 浙江华海药业股份有限公司 | Method for dynamically splitting 2-amino-butyrylamide |
| CN102898324A (en) * | 2012-10-19 | 2013-01-30 | 阜新龙瑞化工有限责任公司 | Method for preparing (S)-2-aminobutanamide hydrochloride |
| CN109678752A (en) * | 2018-12-27 | 2019-04-26 | 南京红杉生物科技有限公司 | A kind of method of asymmetric transformation synthesis L-2- amino-butanamide hydrochloride |
| CN109678752B (en) * | 2018-12-27 | 2021-11-16 | 南京红杉生物科技有限公司 | Method for synthesizing L-2-aminobutanamide hydrochloride by asymmetric transformation |
| CN109503408A (en) * | 2019-01-07 | 2019-03-22 | 宁波赜军医药科技有限公司 | A kind of method for splitting of (S)-(+) -2- amino-butanamide hydrochloride |
| CN109503408B (en) * | 2019-01-07 | 2021-12-21 | 宁波赜军医药科技有限公司 | Resolution method of (S) - (+) -2-aminobutanamide hydrochloride |
| CN113582903A (en) * | 2021-08-25 | 2021-11-02 | 沧州那瑞化学科技有限公司 | Method for synthesizing medicine for treating epilepsy by using L-2-aminobutanamide hydrochloride |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102584622B (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103333942B (en) | A synthetic method for (R)-praziquantel | |
| CN105331651B (en) | The enzyme-chemically preparation method of sitagliptin and its intermediate | |
| CN102584622B (en) | Preparation method of L-2-aminobutanamide hydrochloride | |
| KR102226982B1 (en) | Method for producing pyrrole derivative, and intermediate thereof | |
| US8198485B2 (en) | Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane | |
| Pandey et al. | Generation of all carbon quaternary stereocenters at the C-3 carbon of piperidinones and pyrrolidinones and its application in natural product total synthesis | |
| Zhou et al. | A simple and practical access to enantiopure 2, 3-diamino acid derivatives | |
| Seki | Biological significance and development of practical synthesis of biotin | |
| CN102180823A (en) | Method for refining prolinamide | |
| WO2024216017A2 (en) | Synthesis of ras inhibitors | |
| WO2013114173A1 (en) | A novel process for the preparation of sitagliptin | |
| US8877941B2 (en) | Process for the resolution of medetomidine and recovery of the unwanted enantiomer | |
| US8471016B2 (en) | Process for the preparation of chiral beta amino carboxamide derivatives | |
| CN101417954B (en) | Preparation method of optically pure 3-aminobutanol | |
| US20240383920A1 (en) | Synthesis of ras inhibitors | |
| US20130317109A1 (en) | Process for the preparation of lacosamide | |
| CN101492382A (en) | Novel method for preparing levetiracetam midbody S-(+)-2-aminobutyrate hydrochlorate | |
| US20140127762A1 (en) | Method for producing optically active alpha-substituted proline | |
| CN110092726B (en) | Synthesis method of Bictegravir intermediate | |
| CN105061434B (en) | A kind of preparation method of Sitagliptin phosphate | |
| CN104725248A (en) | Preparation method of R-atomoxetine | |
| RU2741389C1 (en) | Method for preparing intermediate compound for synthesis of medicinal agent | |
| CN116694697A (en) | Preparation method of sitagliptin phosphate monohydrate | |
| CN116640811A (en) | Preparation method of zimetapam intermediate | |
| WO2012081585A1 (en) | Production method for optically active alcohol compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 215433 Suzhou, Taicang Port Development Zone, Taicang port Petrochemical Zone East Road, No. 18 Applicant after: Aba Chemicals Corporation Address before: 215433 Suzhou, Taicang Port Development Zone, Taicang port Petrochemical Zone East Road, No. 18 Applicant before: ABA Chemicals (Suzhou) Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ABA CHEMICALS (SUZHOU) CO., LTD. TO: ABA CHEMICALS CO., LTD |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANTONG ABACHEM CO., LTD Free format text: FORMER OWNER: ABA CHEMICALS CO., LTD Effective date: 20141023 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215433 SUZHOU, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141023 Address after: 226400, Jiangsu, Nantong province Rudong County mouth chemical gathering area Patentee after: NANTONG YABEN CHEMICAL CO., LTD. Address before: 215433 Suzhou, Taicang Port Development Zone, Taicang port Petrochemical Zone East Road, No. 18 Patentee before: Aba Chemicals Corporation |